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. In the serum of healthy individuals, .99.9% of total 25(OH)D is bound to the vitamin D-binding protein (DBP, ;85%) or albumin (;15%); ,0.1% occurs in its free, unbound form (2) . Controversy persists over the physiologic role of total vs free 25(OH)D in humans.
The active vitamin D metabolite, 1,25-dihydroxyvitamin D [1, 25(OH) 2 D], is produced through 1-hydoxylation of 25(OH)D within a target cell that expresses the 1-ahydroxylase, CYP27B1. Although 1,25(OH) 2 D can be produced by many cell types (3), the classic cell type is the renal epithelial cell. Within the kidney, 25(OH)D is internalized by the renal epithelial cell (4) , where it is converted to 1,25(OH) 2 D by the CYP27B1 (4) before re-entering the general circulation and acting in an endocrine fashion at vitamin D receptor (VDR)-possessing tissues (e.g., intestine and bone) to maintain organismal calcium balance (5) . Another tissue that can produce 1,25(OH) 2 D via the CYP27B1 is the parathyroid; 25(OH)D is internalized from the extracellular space by the parathyroid cell and converted to 1,25(OH) 2 D. 1,25(OH) 2 D then acts in a VDR-directed intracrine mode to suppress PTH production and secretion (6) (7) (8) (9) (10) 
Materials and Methods

Study participants
Measurements
At each of the four study visits, serum was collected, and unused specimens were stored at 280°C. Relevant to this current study, we previously measured free 25(OH)D and intact PTH. Free 25(OH)D was assayed by using an antibody-based method from Future Diagnostics as previously described. The assay limit of detection is 1.9 pg/ml. In the range of concentrations measured, the coefficient of variation (CV) was #7%. PTH was measured by electrochemiluminescence immunoassay (Roche Cobas). Intraassay and interassay CV were 0.8% to 1.5% and 1.5% to 1.8%, respectively. In addition to the previously measured analytes, we also assayed total 25(OH)D, 1,25(OH) 2 D, and 24,25(OH) 2 D from previously frozen serum by using liquid chromatography/tandem mass spectrometry (Heartland Assays). For total 25(OH)D, intraassay and interassay CVs were 4.0% and 5.0%, respectively. For 1,25(OH) 2 D, intra-assay and interassay CVs were 4.0% and 5.0%, respectively. For 24,25(OH) 2 D, intra-assay and interassay CVs were 3.0% and 6.0%, respectively.
Statistical analyses
For this study, our goal was not to determine whether D3 vs 25(OH)D3 is a superior approach for vitamin D repletion. Rather, we aimed to gain insight into the relative importance of total vs free 25(OH)D in human physiology. We operationalized this objective by assessing how within-individual increases in total and free 25(OH)D during aggressive repletion [whether by D3 or 25(OH)D3] relate to changes in 24,25(OH) 2 D and PTH during the same time period. We therefore analyzed our vitamin D3-treated and 25(OH)D3-treated participants as a single cohort to maximize statistical power and adjusted for supplementation regimen in all analyses.
We generated descriptive statistics of continuous clinical covariates and biochemical measurements and confirmed their normal distributions. Within-individual changes in each biochemical measurement between successive study visits (i.e., from baseline to 4 weeks, from 4 weeks to 8 weeks, and from 8 weeks to 16 weeks) were examined by the paired t test. Associations between intraindividual changes in total or free 25(OH)D between successive visits (primary predictor in separate analyses) and change in 24,25(OH) 2 D (outcome variable) during the same time period were assessed by using multivariable linear regression. Covariates included coincident change in 1,25(OH) 2 D and supplementation regimen. Associations between intraindividual changes in total or free 25(OH)D between successive visits (primary predictor in separate analyses) and change in PTH (outcome variable) during the same time period were also assessed by using multivariable linear regression. Covariates included coincident change in calcium and supplementation regimen. To test whether supplementation regimen modified the associations between change in total or free 25(OH)D with change in 24,25(OH) 2 D or PTH, we tested for interactions between supplementation regimen and change in total or free 25(OH)D. All analyses were performed using STATA, version 14 (StataCorp, College Station, TX).
Results
Participant characteristics
A total of 35 participants were included in this analysis; 16 and 19 received D3 and 25(OH)D3, respectively. Mean age of the entire cohort was 35.1 6 10.6 years. Mean total and free 25(OH)D at baseline were 16.6 6 3.0 ng/mL and 4.6 6 1.0 pg/mL, respectively. Baseline 24,25(OH) 2 D and PTH were 1.3 6 0.5 ng/mL and 37.2 6 16.3 pg/mL respectively ( Table 1) .
Effects of D3 or 25(OH)D3 on serum vitamin D metabolites
Figures 1 and 2, and (Table 3 ). There were no significant interactions between supplementation regimen and change in total or free 25(OH)D, suggesting that supplementation regimen did not modify the associations between rises in total or free 25(OH)D with increase in 24,25(OH) 2 D.
Associations between total vs free 25(OH)D and PTH
From baseline to the 4-week follow-up visit, rise in free 25(OH)D (P = 0.01), but not total 25(OH)D (P = 0.5), was associated with a decrease in PTH. Between weeks 4 and 8, and then again from weeks 8 to 16, rises in neither total nor free 25(OH)D were related to decline in PTH (P . 0.5 for all). All analyses were adjusted for change in serum calcium and supplementation regimen (Table 4 ). In addition, supplementation regimen did not modify the associations between rises in total or free 25(OH)D with decrease in PTH.
Adherence
Adherence, assessed by pill count, was 91.0% for the entire cohort after 16 weeks of supplementation.
Safety
Hypercalcemia, hypercalciuria, or nephrolithiasis did not occur during the study. Serum and urinary (18) (19) (20) (21) (22) (23) (24) (25) (26) . Some studies report stronger associations between free or bioavailable 25(OH)D and these measures (18, 19, 23, 26) , whereas others do not (20, 21, 24, 25) . There are limited data on whether dynamic, withinindividual changes in total vs free 25(OH)D are more is more efficient in parts of the kidney (e.g., the distal tubule) that do not express megalin (4) . Another possible explanation is that free 25(OH)D is indeed physiologically relevant in vivo, even in megalin-expressing target tissues. This notion is supported by evidence that free 25(OH)D enters the monocyte (which also expresses megalin) to modulate VDR-directed expression of antimicrobial peptides (28, 29) . This is also supported by animal data confirming that DBP (30) .
The clinical implication of our findings is that early in the course of vitamin D repletion, entry of free 25(OH)D from the extracellular compartment into target kidney and parathyroid cells may be physiologically important. This suggests that a vitamin D supplementation regimen that more rapidly and robustly raises free 25(OH)D levels may be preferable. In this regard, we previously found that 25(OH)D3 is superior to a bioequivalent dose of D3 (16) . In vitamin D-deficient individuals, it may therefore be reasonable to consider using 25(OH)D3 as an initial option, followed by maintenance with parent vitamin D (16) . The fact that 1,25(OH) 2 D levels did not increase significantly due to diversion of 1,25(OH) 2 D down the CYP24A1 pathway suggests that this approach would not expose patients to higher risk for vitamin D toxicity.
Several weaknesses warrant mention. First, the study sample size was relatively small. As a result, we pooled our D3 and 25(OH)D3 study participants together for all analyses. Given the different pharmacokinetics between D3 vs 25(OH)D3, we ideally would have analyzed these participants separately. However, the pattern of change in the various vitamin D metabolites was similar between D3 and 25(OH)D3 (16, 31 2 D produced by cells that did not express megalin. Finally, our study was relatively short, which may, in part, explain why PTH did not decrease significantly during the 16-week supplementation regimen (32) .
To conclude, we aimed to assess whether entry of free 
